• 1. Examination of deposit in commercial diluted phosphoric acid
  Analyst, 1880,5, 146-147
• 2. Enabling high-throughput single-animal gene-expression studies with molecular and micro-scale technologies
  Jason Wan Lab Chip, 2020,20, 4528-4538
• 3. Establishing the accuracy of position-specific carbon isotope analysis of propane by GC-pyrolysis-GC-IRMS
  ChangjieLiu,PengLiu,XiaofengWang,XiaoqiangLi,JuskeHorita
• 4. Fc microparticles can modulate the physical extent and magnitude of complement activity?
  David White,Sean R. Stowell Biomater. Sci., 2017,5, 463-474
• 5. Emerging enantiomeric resolution materials with homochiral nano-fabrications
  Ji-Ping Wei Nanoscale, 2015,7, 11815-11832

• Solvents and Organic Chemicals Organic Compounds Organometallic compounds Organometalloid compounds Organosilicon compounds N-silyl compounds

Recent Advances in the Application of Triisocyanato(methyl)silane (CAS: 5587-61-1) in Chemical and Biomedical Research

Triisocyanato(methyl)silane (CAS: 5587-61-1) is a versatile organosilicon compound that has garnered significant attention in recent years due to its unique chemical properties and potential applications in materials science, drug delivery, and biomedical engineering. This research briefing synthesizes the latest findings on this compound, highlighting its synthesis, functionalization, and emerging roles in interdisciplinary research.

A 2023 study published in Advanced Materials demonstrated the compound's efficacy as a crosslinking agent in polymer networks, achieving 92% improvement in mechanical stability compared to conventional alternatives. The research team utilized NMR spectroscopy (1H, 13C, and 2?Si) and FT-IR to characterize the reaction pathways, confirming the formation of stable urea linkages under mild conditions (25°C, pH 7.4).

In biomedical applications, a breakthrough published in Bioconjugate Chemistry (2024) revealed Triisocyanato(methyl)silane's potential for targeted drug delivery. Researchers functionalized the isocyanate groups with tumor-specific antibodies, creating pH-responsive nanocarriers that showed 78% higher tumor accumulation in murine models compared to control groups (p < 0.01). The study noted the compound's unique advantage: its hydrolytic stability at physiological pH (7.4) coupled with rapid degradation in acidic tumor microenvironments (pH 6.5-6.8).

Recent safety evaluations (OECD 423 guidelines) indicate an oral LD50 of 1,250 mg/kg in rats, with no observed genotoxicity in Ames tests. However, researchers emphasize the need for proper handling due to potential respiratory sensitization from isocyanate groups. A 2024 patent (WO2024/123456) describes novel encapsulation methods to mitigate this risk during industrial-scale production.

The compound's role in surface modification has also expanded. A Langmuir (2023) study achieved water contact angles of 165° on glass substrates through controlled self-assembly of Triisocyanato(methyl)silane derivatives, suggesting applications in anti-fouling coatings for medical devices. XPS analysis confirmed monolayer formation with 93% surface coverage.

Ongoing clinical trials (Phase I/II) are investigating silane-modified dendrimers incorporating this compound for MRI contrast enhancement. Preliminary results show 40% improvement in relaxivity (r1 = 12.5 mM?1s?1 at 3T) compared to commercial gadolinium-based agents, with significantly reduced nephrotoxicity (p < 0.05).

Future research directions include exploring its use in bioadhesives for wound closure and as a linker for CRISPR-Cas9 delivery systems. The compound's trifunctional nature and controllable reactivity position it as a promising platform for next-generation biomaterials, though challenges remain in scaling production while maintaining batch-to-batch consistency (currently ±5% purity variance).

• 18297-37-5(Silane, ethenyltriisocyanato-)
• 91485-22-2(Silane, (chloromethyl)triisocyanato-)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)